doc, agree. Stock has made a nice move up with good volume, now some give back on very light volume. And, the day isn't over yet....
Yes, single layer. Keep in mind there was a test of their product years ago and it did no better than standard care. it is a pretender not a contender AND hopelessly behind MDXG.
I agree with Loris. The current dividend is based on the snap shot in Q1 of relatively few properties prodiucing a full quarter of cash flow. Once all in for full quarter plus refis dividend could be double current rate. if not, we are in the wrong stock cause absent the diviend being way higher than what it is now the stock is fairly valued where it is. And, do not forget, there one and ONLY one reason McBride and the new President are here and that is to sell the company. That is their sole charge..everything being done now is just prep work. I still think there is a 50% chance of a sale before year end, 90% chance by end of Q1 2016 and 100% by end of Q2 2016.
They are modeling 16 cents EPS in 2016 for a PE of about 12
We are initiating coverage of Antares Pharma with an Overweight rating and $3.50
PT. Antares’ Vibex self-injection technology in our view positions the company for
significant value creation. This is in the context of two potentially transformative shotson-
goal: (1) a generic version of $1B+ brand EpiPen, known as Vibex Epinephrine
(partnered with Teva, who could launch as early as 6/22/15, per its settlement with
Mylan); and (2) a subcutaneous (SC) injectible form of testosterone, known as Vibex
QuickShot Testosterone (QS T), which could be on the market in 2018. With combined
2018 revenue from Vibex Epinephrine, QS T and Otrexup, an SC, self-injectible form of
methotrexate (MTX) that the company launched last year, that could be well in excess
of $100M, ATRS shares are attractive in our view in the context of a market cap of only
silverfox, ALQA is 1/12th the size of MDXG. Even if Biovance could compete, someday, MDXG will be gone by them and, MDXG has a lot more going on that just where Biovance might compete
I se nothing in OSIR's 10Q indocating that they lost pass through nor any mention of it in the note from Brean on OSIR last week.
Thought by who? I don't know anyone nor have I heard anyone at the company who considered ALQA as a threat.
silverfox, yes Northland bought Summer Street. The new analyst has a very interesting background
Mark Landy has spent 15 years on Wall Street and in the medical device industry and has significant transactional experience in both the developed and emerging markets. Mr. Landy has been recognized in numerous Institutional Investor Magazine Top Analyst Polls and was named to the “2008 PharmaVOICE 100″ list of the top 100 most inspirational people in the life science industry. Mr. Landy graduated from the University of The Witwatersrand, Johannesburg, South Africa and worked as an oral-facial surgeon in South Africa and the United Kingdom before studying finance and management at the Wharton School of Business
Wait..even better. It wasn't Suraj who upgraded. Sue to "reallocation of resources" they transfereed coverage to another analyst that upgraded to $10 target. Maybe Suraj was taken off the stock due to cluelessness or conflict of interest?
The only bigger scam exchange than the Toronto exchange is the Vancouver exchange. An automatic disqualfier for me.
Millrace Asset Group filed its 13F. At 12/31, they held 263,207 shares. Per the 13F they hold at 3/31 2,089,911 so bought a ton of stock during Q1
It is undervalued because it is underfollowed. Very few other than long terners know anything about the company. It is the last pieces of the restructure that I expect will unlock the value. As a "REIT" it's hard to say its undervalued right now with the yield in the high 4% area. For what is still a fairly high risk REIT that yield is about what one would expect. Company needs to get to having all facilities 100% rented for a full quarter, refi debt to lower interest rate, couple acquisitions, etc to get the yield closer to 10%. At that point the value of the company to a larger playeys rises significantly.
how_bout. Ironic you should use the phrase "meaningless abstracts". Similar term used by most of us here about your "meaningless posts".